A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2

Conditions: Psoriasis

Treatments: Drug: BMS-582949; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00399906

IM119-013

Details and patient eligibility

About

The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.

Enrollment: 99 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Males and Females (not nursing or not pregnant)
• 18-75 years of age
• Diagnosis of moderate to severe psoriasis for at least six months at the time of screening
• Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

99 participants in 4 patient groups, including a placebo group

A1

Active Comparator group

Description:

10 mg

Treatment:

Drug: BMS-582949

A2

Active Comparator group

Description:

30 mg

Treatment:

Drug: BMS-582949

A3

Active Comparator group

Description:

100 mg

Treatment:

Drug: BMS-582949

P1

Placebo Comparator group

Description:

10 or 100 mg

Treatment:

Drug: Placebo